ARTICLE | Company News
Gilead's Sovaldi gets Chinese approval
September 25, 2017 9:54 PM UTC
Gilead Sciences Inc. (NASDAQ:GILD) said China FDA approved Sovaldi sofosbuvir to treat HCV genotypes 1-6 infection as part of an antiviral treatment regimen in patients ages 12 and older.
Gilead said the nucleotide analog HCV NS5B polymerase inhibitor is the first HCV drug from the company to receive Chinese approval. Last year, CFDA selected Sovaldi for expedited review along with Gilead's Harvoni ledipasvir/sofosbuvir, a fixed-dose combination of Sovaldi and ledipasvir, an HCV NS5A protein inhibitor (see BioCentury Extra, April 25, 2016)...